SCHEMBL14498166

SCHEMBL14498166

COc1cc2nc(C)cc(N)c2cc1OC

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 1/20 0.55
NCF1 P14598 1/20 0.50
NR4A2 P43354 1/20 0.50
ADRA1D P25100 1/20 0.49
ADRA1A P35348 1/20 0.49
ADRA1B P35368 1/20 0.49
LMNA P02545 1/20 0.49
GLA P06280 1/20 0.49
POLB P06746 1/20 0.49
GAA P10253 1/20 0.49
SMARCA2 P51531 1/20 0.49
KMT2A Q03164 1/20 0.49
ALDH1A1 P00352 1/20 0.49
CASP1 P29466 1/20 0.49
CASP7 P55210 1/20 0.49
HSD17B10 Q99714 1/20 0.49
PDE3B Q13370 1/20 0.47
PDE3A Q14432 1/20 0.47
ACHE P22303 1/20 0.46
TERT O14746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24659389 0.86 SLC2A1 (0.50) SLC2A1NCF1NR4A2ADRA1DADRA1A
SCHEMBL1297649 0.83 SLC2A1 (0.56) SLC2A1ADRA1DADRA1AADRA1BLMNA
SCHEMBL18535283 0.81 PDE3B (0.50) SLC2A1LMNAGLAPOLBGAA
SCHEMBL13941143 0.79 SLC2A1 (0.52) SLC2A1ADRA1DADRA1AADRA1BLMNA
SCHEMBL19185178 0.78 PDE4A (0.50) LMNAGLAPOLBGAASMARCA2
SCHEMBL18576442 0.78 PDE3B (0.47) SLC2A1LMNAGLAPOLBGAA
SCHEMBL17372585 0.78 MAPT (0.56) LMNAGLAPOLBGAASMARCA2
SCHEMBL8366935 0.75 PDE3B (0.49) POLBGAAALDH1A1PDE3BPDE3A
SCHEMBL437286 0.75 HSD17B10 (0.71) SLC2A1NCF1POLBKMT2AALDH1A1
SCHEMBL7757891 0.75 POLB (0.49) LMNAGLAPOLBGAASMARCA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070142350-A1 THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL- AND PIPERAZINYL-ALKYL CARBAMATES SANOFI-AVENTIS (FR) 2007-06-21 US disclosed
US-20070142350-A1 THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL- AND PIPERAZINYL-ALKYL CARBAMATES SANOFI-AVENTIS (FR) 2007-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142350-A1 THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL- AND PIPERAZINYL-ALKYL CARBAMATES H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR3, H1-2 SLC2A1 1372/4885NCF1 728/4885NR4A2 1029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.